Ajax Therapeutics Funding: $135M Raised, Series C (2024)
Ajax Therapeutics is a Biotech company based in New York, NY. It has raised $135M in total funding. Latest round: Series C.
Ajax Therapeutics funding overview
Ajax Therapeutics is a Biotech company based in New York, NY. Ajax Therapeutics has raised $135M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in May 2024. The round record for Ajax Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Goldman Sachs Alternatives, Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital and 3 others. 9 distinct backers are named across the disclosed rounds.
Ajax Therapeutics at a glance
Total raised
$135M
Latest round
Series C
Latest round date
May 2024
Industry
Biotech
Headquarters
New York, NY
Notable investors
Goldman Sachs Alternatives, Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital, Boxer Capital, Schrödinger, Inc.
Frequently asked about Ajax Therapeutics funding
How much has Ajax Therapeutics raised?
Ajax Therapeutics has raised $135M in total disclosed funding across the rounds on record.
Who has invested in Ajax Therapeutics?
Goldman Sachs Alternatives, Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital are named among the investors backing Ajax Therapeutics.
What was the latest Ajax Therapeutics funding round?
The most recent disclosed round is a Series C, announced in May 2024.
Where is Ajax Therapeutics based?
Ajax Therapeutics is based in New York, NY.
What sector does Ajax Therapeutics operate in?
Ajax Therapeutics is tracked under Biotech from New York, NY, with $135M in disclosed funding.
When did Ajax Therapeutics last raise?
The last disclosed Ajax Therapeutics round closed in May 2024 at Series C.
Ajax Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in New York below to benchmark round size and investor mix.
